Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring ...

Inside TIL therapy: daily hospital routines, caregiver support, chemo and infusion steps, and what recovery questions patients ask most. Interleukin-2 (IL-2) is often the most challenging part of ...

A mother reflects on the "tethered heart" of caregiving, sharing her journey through her son’s rare cancer and offering solidarity to all mothers.

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness.

Fast Track status aims to accelerate development of an autologous dendritic cell immunotherapy for advanced cutaneous melanoma with limited durable benefit from current standards in many patients.

The result of this multidisciplinary synergy is a clear path forward. According to Kasper, the patient leaves the visit with ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...

CURE spoke with Dr. Michael E. Kasper, medical director of radiation oncology at the Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital.